CooperGenomics Revenue and Competitors

Livingston, NJ USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CooperGenomics's estimated annual revenue is currently $17.1M per year.(i)
  • CooperGenomics's estimated revenue per employee is $155,000

Employee Data

  • CooperGenomics has 110 Employees.(i)
  • CooperGenomics grew their employee count by 9% last year.

CooperGenomics's People

NameTitleEmail/Phone
1
Laboratory DirectorReveal Email/Phone
2
Senior Genomics Territory ManagerReveal Email/Phone
3
Global Manager, Quality Assurance and Regulatory ComplianceReveal Email/Phone
4
Senior ResearcherReveal Email/Phone
5
Genetic CounselorReveal Email/Phone
6
Clinical Science LiaisonReveal Email/Phone
7
Laboratory TechnicianReveal Email/Phone
8
Laboratory SupervisorReveal Email/Phone
9
Genetic CounselorReveal Email/Phone
10
Coordinator, Patient and Client ServicesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.5M55-21%N/AN/A
#2
$0.2M10%N/AN/A
#3
$8.5M55-29%N/AN/A
#4
$108.5M5002%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M1503-15%$568MN/A
#9
$1.1M7-42%N/AN/A
#10
$4.5M290%N/AN/A
Add Company

What Is CooperGenomics?

Together as part of the CooperSurgical family, we are the pioneers and global leaders of comprehensive reproductive genetic testing. Through expanded PGD, PGS, and beyond, our team is committed to advancing the field of reproductive genetics, improving outcomes, and empowering families worldwide.

keywords:N/A

N/A

Total Funding

110

Number of Employees

$17.1M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CooperGenomics News

2022-04-17 - Monash IVF Group's 'inaccurate' genetic test potentially robbed these women of viable embryos

One attendee, Tony Gordon from Cooper Genomics, summarised on his LinkedIn page: "The tech is improving but the opinion of the room seemed...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.9M1186%N/A
#2
$24.3M121N/AN/A
#3
$44.1M1259%N/A
#4
$7.5M1317%N/A
#5
$27.9M133-2%N/A